会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Protease inhibitor assay
    • 蛋白酶抑制剂测定
    • US06243980B1
    • 2001-06-12
    • US09035820
    • 1998-03-06
    • Irena BronsteinJohn VoytaMichelle PalmerBonnie Tillotson
    • Irena BronsteinJohn VoytaMichelle PalmerBonnie Tillotson
    • G01N33533
    • G01N33/582C12Q1/37G01N33/581G01N2333/81Y10S436/80Y10S436/805
    • Heterogenous and homogenous assays are provided for the detection of protease inhibitory activity in a sample or target compound, taking advantage of the chemiluminescent characteristics of 1,2-dioxetanes. In the heterogenous assay, a peptide bearing a cleavage site for the protease of interest is provided with a first member of a first ligand binding pair at one end, and a first member of a second ligand binding pair at the other end. The other member of the first ligand binding pair is attached to a surface, which binds the peptide, or protease substrate, to the surface. The peptide substrate is combined with the protease and target compound or sample. Substrate cleavage, if not inhibited, is allowed to occur, and any unbound cleaved fragments are removed. An enzyme complexed with the second member of the second ligand binding pair is added, and allowed to bind to any of the (uncleaved) first member of the second ligand binding pair remaining. Unbound complex is removed, and a 1,2-dioxetane substrate for the enzyme is added. If any peptide substrate has not been cleaved, the dioxetane will chemiluminesce, indicating inhibitory activity. In a homogenous assay, the same substrate bears at one end a fluorescent energy accepting moiety, and at the other end a 1,2-dioxetane or precursor. If the substrate is cleaved by the protease, the dioxetane and the fluorescent moiety are not in close physical relationship, and no energy transfer occurs when the dioxetane is caused to decompose. If cleavage has not occurred, indicating inhibition, when the dioxetane is caused to decompose, energy is transferred to the fluorescing entity, which releases light of a wavelength recognizably distinct from that of the dioxetane.
    • 提供异源和均一的测定法,用于检测样品或目标化合物中蛋白酶抑制活性,利用1,2-二氧杂环己烷的化学发光特性。 在异源测定中,具有目的蛋白酶的切割位点的肽在一端具有第一配体结合对的第一个成员,另一端具有第二配体结合对的第一个成员。 第一配体结合对的另一个成员连接到表面,其将肽或蛋白酶底物结合到表面。 将肽底物与蛋白酶和目标化合物或样品组合。 如果不抑制底物裂解,则可以发生底物裂解,并且去除任何未结合的切割的片段。 加入与第二配体结合对的第二个成员配合的酶,并使其与残留的第二配体结合对的任何(未切割的)第一个成员结合。 去除未结合的络合物,并加入酶的1,2-二氧环乙烷底物。 如果任何肽底物未被切割,二氧杂环丁烷将化学发光,表明抑制活性。 在同质测定中,相同的底物在一端承载荧光能量接受部分,另一端在1,2-二氧杂环丁烷或前体上。 如果底物被蛋白酶切割,二氧杂环丁烷和荧光部分不是很密切的物理关系,当二氧杂环丁烷分解时,不会发生能量转移。 如果没有发生裂解,表明抑制,当二氧杂环丁烷分解时,能量被转移到荧光实体,其释放与二氧杂环丁烷的波长可辨别的波长的光。
    • 4. 发明授权
    • Gangliosides having fluorescent-tagged ceramide moieties
    • 神经节苷脂具有荧光标记的神经酰胺部分
    • US06204002B1
    • 2001-03-20
    • US09091780
    • 1998-12-23
    • Takao IidaYutaka Ohira
    • Takao IidaYutaka Ohira
    • G01N33533
    • C07H15/04G01N33/56983Y02P20/55Y10S435/975Y10S436/80Y10S436/811Y10S436/818
    • The invention provides a compound represented by the following formula (I) wherein m is an integer of 2-15; n is an integer of 0-12; R represents a sugar chain or a derivative thereof; R′ represents a general formula (II) (wherein p is an integer of 0-4, q is an integer of 0-5; r is an integer of 2-5; R12 and R13 are the same or different and each represents a hydrogen atom, a lower alkyl group, an aliphatic acyl group, a nitro group or a nitrile group), R1 represents a hydrogen atom or a protective group of carboxylic acid, R2, R4 and R5 are the same or different and each represents a hydrogen atom, an aliphatic or aromatic acyl group; R3 represents an acetyl group, a glycolyl group or a trifluoroacetyl group; useful as reagent for detecting influenza virus A.
    • 本发明提供由下式(I)表示的化合物,其中m为2-15的整数; n为0-12的整数; R代表糖链或其衍生物; R'表示通式(II)(其中p为0-4的整数,q为0-5的整数; r为2-5的整数; R12和R13相同或不同,各自表示 氢原子,低级烷基,脂族酰基,硝基或腈基),R 1表示氢原子或羧酸的保护基,R 2,R 4和R 5相同或不同,各自表示氢 原子,脂族或芳族酰基; R3表示乙酰基,乙酰基或三氟乙酰基; 用作检测流感病毒A的试剂。
    • 7. 发明授权
    • Non-captive substrate liquid phase immunoassay
    • 非捕获底物液相免疫测定
    • US06632603B1
    • 2003-10-14
    • US08914700
    • 1997-08-19
    • Thomas T. HubscherErik P. Lillehoj
    • Thomas T. HubscherErik P. Lillehoj
    • G01N33533
    • G01N33/585B01L3/5023B01L2300/0825B01L2400/0406G01N33/538G01N2333/4737Y10S435/971Y10S435/975Y10S436/824
    • An immunoassay of a liquid biological specimen for a specific analyte is conducted by forming a test sample by contacting the specimen with: (1) a binding substance of a ligand, antiligand or receptor capable of binding the analyte and (2) a detector substance of a colloidal gold or silver labeled ligand or antiligand to form a test sample. The test sample is applied by flowing onto a defined zone of an insoluble porous support film having a pore size impassable to a complex formed between the analyte, if present, with the binding substance and the detector substance, but passable to the binding substance and detector substance while remaining uncomplexed in the absence of the desired analyte. If the analyte is present in the test specimen, the detector substance binds with the analyte and the binding substance to form a visually inspectable complex on the surface of the porous support film. After application of the test sample to the porous support, the surface of the porous support is visually inspected for color to determine the presence and quantity or the absence of the analyte being assayed.
    • 对特定分析物的液体生物样品进行免疫测定,通过使样品与以下物质接触来形成测试样品:(1)能够结合分析物的配体,反配体或受体的结合物质和(2)检测物质 胶体金或银标记的配体或反配体以形成测试样品。 通过流动到不溶性多孔载体膜的限定区域上来施加测试样品,所述不溶性多孔载体膜的孔隙尺寸不能通过分析物(如果存在)与结合物质和检测物质形成的复合物通过,但可通过结合物质和检测器 物质,同时在不存在所需分析物的情况下保持未络合。 如果分析物存在于测试样品中,检测器物质与分析物和结合物质结合,以在多孔载体膜的表面上形成目视检查的复合物。 在将测试样品施加到多孔载体上之后,目视检查多孔载体的表面的颜色,以确定待分析物的存在和数量或不存在。